{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"DLTs were defined as protocol-defined toxicities occurring up to and including on Day 28, except those with a clear alternative explanation. Toxicities with a clear alternative explanation (e.g., due to disease progression) or transient (≤72 hours) abnormal laboratory values without associated clinically significant signs or symptoms based on investigator determination could have been deemed non-DLTs.","groups":[{"description":"Participants received INCB099280 50 milligrams (mg) once daily (QD) plus adagrasib 400 mg twice daily (BID) for up to 2 years.","id":"OG000","title":"INCB099280 50 mg QD Plus Adagrasib 400 mg BID"},{"description":"Participants received INCB099280 100 mg BID plus adagrasib 400 mg BID for up to 2 years.","id":"OG001","title":"INCB099280 100 mg BID Plus Adagrasib 400 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT-Evaluable Population: all participants in Part 1 who had a DLT by the end of the first treatment cycle, or received at least 75% of the planned doses during the first treatment cycle, or discontinued study treatment due to a DLT or treatment-related adverse event, even if adagrasib was not started","reportingStatus":"POSTED","timeFrame":"up to Day 28","title":"Number of Participants With Dose-limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}